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Abstract
The accurate measurement of health-related quality of life (HRQoL) and the value of improving it for patients are essential for
deriving quality-adjusted life years (QALYs) to inform treatment choice and resource allocation. The objective of this reviewwas
to identify and describe the approaches used to measure and value change in HRQoL in trial-based economic evaluations of heart
failure interventions which derive QALYs as an outcome. Three databases (PubMed, CINAHL, Cochrane) were systematically
searched. Twenty studies reporting economic evaluations based on 18 individual trials were identified. Most studies (n = 17)
utilised generic preference-based measures to describe HRQoL and derive QALYs, commonly the EQ-5D-3L. Of these, three
studies (from the same trial) also used mapping from a condition-specific to a generic measure. The remaining three studies used
patients’ direct valuation of their own health or physician-reported outcomes to derive QALYs. Only 7 of the 20 studies reported
significant incremental QALY gains.Most interventions were reported as being likely to be cost-effective at specified willingness
to pay thresholds. The substantial variation in the approach applied to derive QALYs in the measurement of and value attributed
to HRQoL in heart failure requires further investigation.
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Introduction
Heart failure (HF) is common and costly to manage; it ac-
counts for 1–3% of health care expenditure in Western
Europe, North America and Latin America and causes or com-
plicates about 5% of all US and European hospital admissions
amongst adults [1]. The costs, prevalence and complexity of
treating HF are increasing, along with ageing of the popula-
tion. Identifying and supporting patient access to interventions
that are both clinically and cost-effective are required to opti-
mise the use of resources.
Health-related quality of life (HRQoL) is an important out-
come measure in HF that is influenced by physical, emotional
or social function, role performance, pain and fatigue. There
has been a drive towards patient-reported outcome measures
(PROMs) and patient-reported experience measures (PREMs)
in health care systems, including the British NHS. Thus, the
accurate measurement and valuation of HRQoL and its re-
sponse to therapy are essential for choosing treatments and
allocating resources. When considering the cost-
effectiveness of interventions, the quality-adjusted life year
(QALY) is the outcome of choice for most decision-making
bodies (such as the National Institute for Health and Care
Excellence, NICE in the UK [2]), as it accounts for both
HRQoL and survival, and their changes, in a single metric.
QALYs are typically obtained from generic preference-based
measures (PBMs) such as the EQ-5D (three- or five-level
version) to provide utility values and these are multiplied by
the duration lived in a health state. PBMs describe HRQoL as
a series of health states and then assign a utility weight to each
health state on a common scale, according to the preferences
of members of the public for being in different health states.
An alternative method for generating utility values is the direct
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elicitation of utilities from the patients themselves, using val-
uation methods such as the time trade-off (TTO), standard
gamble (SG) or discrete choice experiment (DCE). QALY
gains can subsequently be compared between interventions
for use in economic evaluation.
Accurate measurement and valuation of HRQoL relies
on the availability of a PBM that is sensitive to change.
Generic PBMs are commonly used in economic evaluation,
and there is evidence to support the validity and reliability
of the commonly used EQ-5D-3L in cardiovascular disease,
particularly in moderate to severe health states [3].
However, generic measures may lack sensitivity to change
as they do not capture important symptoms of HF such as
breathlessness, loss of self-control and tiredness [4, 5].
Condition-specific measures of HRQoL such as the
Minnesota Living With Heart Failure (MLWHF) question-
naire and Kansas City Cardiomyopathy Questionnaire
(KCCQ) capture these symptoms. The KCCQ has been
reported to be more sensitive than the generic EQ-5D-3L
and Short-Form Survey (SF)-12 measures, particularly for
detecting small rather than large changes in disease severity
[3, 4, 6, 7]. Consequently, researchers have called for the
inclusion of condition-specific measure alongside generic
measures when capturing effectiveness for these conditions
[8].
Whilst condition-specific measures are sensitive in cap-
turing HRQoL, none of the available condition-specific
measures in HF are preference-based [9]. Therefore, they
cannot be used directly to generate QALYs. Other ap-
proaches such as mapping have been used to generate
utility weights where no PBM was used, meaning a HF-
specific measure could be used to measure HRQoL and
this could be mapped to a measure such as the EQ-5D to
generate utility weights. However, mapping is only appro-
priate if both measures are appropriate for the patient
population, and relies on overlap between the two mea-
sures. Any symptoms captured in the HF-specific measure
are unlikely to feature in the mapping model, meaning the
sensitivity of the HF-specific measure to change is not
necessarily maintained when mapped to EQ-5D.
Therefore, the lack of availability of utility indices for
condition-specific measures is likely to limit their use in
the economic evaluation of HF interventions.
Accordingly, we conducted a systematic review to
identify and describe the approaches used to measure
and value change in HRQoL in trial-based economic
evaluations of HF interventions which derive QALYs as
an outcome measure. We sought to investigate the extent
to which utility weights are generated using different
approaches: generic PBM, mapping to a PBM or directly
ascertained using a valuation method. A secondary ob-
jective was to identify whether published papers reported
whether interventions for HF were cost-effective.
Methods
Protocol and registration
The review protocol is registered at the International
Prospective Register of Systematic Reviews (PROSPERO)
and can be accessed at: https://www.crd.york.ac.uk/prospero/
display_record.php? RecordID = 78519 registration number
CRD42017078519.
Eligibility criteria
The inclusion and exclusion criteria are presented in Table 1.
Randomised controlled trials that were published in full, in
English, and compared costs and benefits expressed as
QALYs as an outcome measure were included if they evalu-
ated an intervention designed to investigate the treatment or
management of HF in adults (≥ 18 years old). There were no
upper age limit, sex or publication date restrictions. Studies
that included participants without HF, systematic reviews,
modelled studies, meta-analyses and those published as ab-
stract only were excluded.
Search strategy
PubMed Central, Cumulative Index to Nursing and Allied
Health Literature (CINAHL) and the Cochrane Library
(NHS Economic Evaluation Database) were searched be-
tween 26 June and 3 July 2017, with no date restrictions.
The following search terms were used:
PubMed Central: Bheart failure^[Abstract] AND (cost
utility analysis [Abstract] OR CUA [Abstract] OR eco-
nomic evaluation [Abstract] OR cost effectiveness
[Abstract])
Cochrane Library: Bheart failure^ AND (cost utility anal-
ysis OR CUA OR economic evaluation OR cost
effectiveness)
CINAHL: Bheart failure^ AND (cost utility analysis OR
CUA OR economic evaluation OR cost effectiveness)
Study selection
The results from the databases were combined, and duplicates
were removed. Papers were screened on their title and ab-
stract. Potentially relevant papers were retrieved in full and
screened against the inclusion/exclusion criteria.
Bibliographies of relevant papers were hand-searched for
any sources potentially missed within the database searches.
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Data extraction
The characteristics and results of relevant studies were extract-
ed based on an amended version of a standardised data col-
lection form recommended by the Cochrane Training
(Cochrane Library: http://training.cochrane.org/resource/
data-collection-forms-intervention-reviews). The form was
amended to collect characteristics relevant to describe the
economic evaluation and HRQoL measure and valuation.
The following were extracted:
& Measurement and valuation of HRQoL including measure
and approach used to generate utility weights
& The elicitation method, tariff and population used to de-
rive the utility weights used to value HRQoL
& The mean difference in QALYs between the intervention
and control groups from baseline to follow-up with signif-
icance levels and confidence intervals (if available)
& Incremental cost per QALYof intervention(s) and indica-
tion of the level of uncertainty (such as confidence inter-
val) around that estimate
& Probability of cost-effectiveness at a specified threshold
Where a study cited other papers as the source of the utility
weights to derive QALYs, the original source of utility
weights was retrieved to enable a description of the approach
to deriving QALYs.
Quality assessment
The Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) statement was used to assess the
reporting quality of studies [10]. Each of the 24 items in the
CHEERS checklist was assigned a weight ranging from zero
to two (representing studies that did not report, reported poor-
ly or reported well) which were used to calculate an average
reporting quality score.
Results
Study selection
A total of 492 citations were identified by the database searches,
with 11 additional citations identified by hand searching (Fig. 1).
Twenty studies were included in the final review (Table 2).
Study characteristics
The 20 papers included within the review were trial-based
evaluations based on data sourced from 18 individual
Database search (492)
Unduplicated (395) Additional citations
identified from hand-
search or reference lists 
(11)
Filtered by title and
abstract (406)
Excluded by title and 
abstract (320)
Filtered by full text (86)
Excluded (66):
Prevention (1)
Abstract only (4)
Study design (39)
Inclusion of 
moborbidities/other 
participant groups (10)
Not based on trial data (2)
Model-based studies (10)
Studies included (20)
Fig. 1 Study selection
Table 1 Inclusion and exclusion
criteria Inclusion criteria (if all of the following met) Exclusion criteria (if any of the following met)
1. Original research 8. Papers other than in the English Language
2. Adults (aged 18 and over)
of any sex or ethnic group
9. Design/protocol papers, systematic reviews,
meta-analyses and commentaries/editorials
3. Interventions designed to treat
or manage heart failure
10. Effectiveness estimates not based
on actual trial data (e.g. hypothetical intervention
or summarised effect)
4. Trial-based analyses based on data
from randomised control trials
11. Trials investigating conditions other
than heart failure
5. Comparison of costs and benefits expressed as QALYs 12. Studies published as abstract only
6. Published papers in English 13. Prevention and diagnostic interventions
7. Participants with heart failure 14. Model-based studies
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Table 2 Trial-based evaluations (n = 20 cost–utility analyses based on 18 trials)
Study design Study population
Author and year Data source Setting; perspective Intervention vs. control Discount
rate
Sample
size (n)
Age
(mean)
Sex
(males
%)
NYHA†‡
(%)
Agvall et al.
(2014)
[19]
The benefits of using a heart failure
management programme in Swedish
primary health care trial
Sweden; health care system§ Management program
vs. usual care
NR 160 75 69.4 I (6)
II (59)
III (36)
Blomstrom et al. (2008)
[11]
The Cardiac Resynchronisation
in Heart Failure trial (CARE-HF)
Europe; Denmark, Finland
and Sweden; health
care system
Pharmacological therapy (PT)
with cardiac resynchronisation
therapy vs. PT alone
3% 813 I 67*
C 66
73.4 III (87)
IV (13)
Boyne et al. (2013)
[20]
Telemonitoring in Heart Failure
trial (TEHAF)
The Netherlands;
health care system
Telemonitoring vs. usual care 0% 382 71 59 II (57)
III (40)
IV (3)
Calvert et al. (2005)
[12]
CARE-HF Europe; UK health care system Pharmacological therapy (PT)
with cardiac resynchronisation
therapy vs. PT alone
3.5% 813 I 67*
C 66
73.4 III (87)
IV (13)
Capomolla et al. (2002)
[15]
Own trial Italy; societal Day-hospital management
vs. usual care
5% 234 56 83.8 I-II (65)
III-IV
(35)
Cui et al. (2013)
[27]
Testing the Effectiveness of Health Lines
in Chronic Disease Management
of Congestive Heart Failure
trial (Health Lines)
Canada; health care system Health Lines (I1) and Health
Lines and in-house monitoring
(I2) vs. standard treatment
0% 179 75 52 II (22)
III (47)
IV (31)
Hansson et al. (2016)
[16]
Person-Centred Care in Patients
with Chronic Heart Failure trial
(PCC-HF)
Sweden; health care system Person-centred vs. conventional
care
0% 248 I 77.5
C 80.3
58.9 I (5)
II (35)
III (54)
IV (7)
Hebert et al. (2008)
[21]
Own trial US; societal and payer Nurse-managed disease
management vs. usual care
NR 406 59.4 54 I (18)
II (22)
III (14)
IV (45)
Maniadakis et al. (2011)
[13]
CARE-HF Europe; Greek health care
system
Pharmacological therapy (PT)
with cardiac resynchronisation
therapy vs. PT alone
3% 813 I 67*
C 66
73.4 III (87)
IV (13)
Maru et al. (2015)
[22]
Which Heart Failure Intervention
Is Most Cost-Effective & Consumer
Friendly in Reducing Hospital
Care trial (WHICH)
Australia; health care system Home vs. clinic based care 5% 280 71 73 II/III (85)
IV (15)
Mejia et al. (2014)
[23]
Nurse Facilitated Self-management
Support for People with Heart Failure
and their Family Carers
trial (SEMAPHFOR)
UK; National Health Service Nurse facilitated cognitive
behavioural self-management
programme vs. usual care
0% 260 70.6 72 II (68)
III (30)
IV (2)
Neumann et al. (2015)
[24]
Interdisciplinary Network for Heart
Failure trial (INH)
Germany; societal Nurse-led management
programme vs. usual care
NR 715 I 67.7
C 69.4
70.6 I (2)
II (58)
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Table 2 (continued)
Study design Study population
Author and year Data source Setting; perspective Intervention vs. control Discount
rate
Sample
size (n)
Age
(mean)
Sex
(males
%)
NYHA†‡
(%)
III (36)
IV (4)
Patel et al. (2008)
[25]
Own pilot trial Sweden; health care system§ Home vs. conventional care NR 31 I 77
C 78
67.7 II (3)
III (94)
IV (3)
Postmus et al. (2016)
[17]
Coordinating Study Evaluating
Outcomes of Advising and Counselling
in Heart Failure trial (COACH)
The Netherlands; health services Basic (I1) and intensive (I2)
additional nurse support
vs. usual care
NR 1023 71 62 II (50)
III (46)
IV (4)
Reed et al. (2010)
[29]
Heart Failure: a Controlled Trial
Investigating Outcomes of Exercise
Training trial (HF-ACTION)
US, Canada and France; societal Exercise training plus usual
care vs. usual care
3% 2331 I 59.2
C 59.3
71.6 II (63)
III (36)
IV (1)
Reilly et al. (2015)
[26]
Quality HF-diabetes trial US; health care services Self-care vs. usual care 0% 134 57.4 88 II (42)
III (50)
IV (8)
Sahlen et al. (2016)
[18]
Palliative Advanced Home Care
and Heart Failure Care trial (PREFER)
Sweden; health services provider Palliative advanced home
and heart failure
care vs. usual care
NR 72 I 81.9
C 76.6
72.2 III (71)
IV (29)
Sánchez et al. (2010)
[31]
Own trial Spain; hospital Peritoneal dialysis
vs. conservative therapy
NR 17 64 65 III (59)
IV (41)
Sanders-van Wijk et al.
(2013)
[30]
Intensified vs. Standard Medical
Therapy in Elderly Patients
with Congestive Heart Failure
trial (TIME-CHF)
Switzerland and Germany;
third-party payer
N-Terminal Pro-B-Type
natriuretic-guided therapy
vs. symptom-guided therapy
0% 467 76 66 II (27)
III-IV
(73)
Zanaboni et al. (2013)
[28]
Evolution of Management Strategies
of Heart Failure Patients with
Implantable Defibrillators trial
(EVOLVO)
Italy; health care system
and patient
Remote monitoring
vs. conventional
in-person evaluations
NR 200 I 66*
C 69*
78.5 I (12)
II (70)
III (19)
I Intervention, C control, I1 intervention 1, I2 intervention 2, NR not reported
*Median
†Components may not add to 100 due to rounding
‡New York Heart Association classification (I to IV)
§Assumed as not explicitly reported in paper
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randomised controlled trials (RCT), with three papers [11–13]
based on the Cardiac Resynchronisation in Heart Failure
(CARE-HF) trial [14]. The date of publishing ranged from
2002 [15] to 2016 [16–18].
The majority of papers (n = 16) focused on management in-
terventions as opposed to treatment (n = 4) for HF. Management
interventions included the following: nurse led [17, 19–26],
telemonitoring [27, 28], outpatient clinic based [15], person-
centred care [16, 18], exercise training [29] and NT-proBNP-
guided therapy [30]. Treatment interventions included cardiac
resynchronisation therapy [11–13] and peritoneal dialysis [31].
Most papers adopted the perspective of their respective coun-
tries’ health care system or third-party payers, and one study [28]
included the costs and effects from a patient perspective. The
remaining studies adopted a societal [15, 24, 29], a combination
of both a societal and payer [21] or a single hospital perspective
[31]. The study perspective was not explicitly reported in two
papers [19, 25]; a health care system perspective was assumed in
both because of the costings involved within the trials.
Sample sizes within the trials ranged from 17 [31] to 2331
[29] with a total of 7952 participants across all studies (ac-
counting for the individuals in the CARE-HF trial only once).
The overall population studied within the trials was predom-
inantly men (68.2%) with mean/median ages ranging from
56 ± 10 [15] to 81.9 ± 7.2 years [18]. Fifteen papers reported
average participant ages of > 60 years. Three papers excluded
participants based on age: those aged under 21 (with an age
limit of 82) [26], under 40 [27] and under 60 years [30].
New York Heart Association (NYHA) functional class, a
commonly used physician-assessed tool measuring patient’s
functional ability in HF, was reported in all papers reviewed.
Seventeen trials reported individual participant category num-
bers for each NYHA class (NYHA classes were grouped in
three studies [15, 22, 30] and therefore were not included in
the following summary). Most participants were assigned to
NYHA class II (47.5%) and III (43.7%) rather than class IV
(the most severe; 6.9%) or class I (asymptomatic; 1.9%).
Overall, eight reports had exclusion criteria in relation to par-
ticipant NYHA class, with five studies excluding NYHA class
I [22, 25, 26, 29, 30] and CARE-HF (three reports) excluded
NYHA class I and II [11–13].
The discount rate used for assessing costs and effects in the
trial-based economic evaluations ranged from to 0% [16, 20,
23, 26, 27, 30] in the studies who had a follow-up of less than
12 months to 3% [11, 13, 29], 3.5% [12] and 5% [15, 22]. No
discount rate was reported in eight studies [17–19, 21, 24, 25,
28, 31].
Measurement and valuation of HRQoL to derive
QALYs
A summary of the approach used to derive QALYs in the
base-case analyses for the 20 studies is provided in Table 3.
Description of health states used to derive QALYs
Most (n = 17) of the studies used a validated, generic PBM of
HRQoL completed by participants to describe the health sta-
tus of participants. The EQ-5D was the most commonly used
(n = 13), with most studies using the 3L version. Two studies
did not indicate the version of EQ-5D used (3L or 5L) [24, 28]
but seem likely to have used the 3L version based on publi-
cation date (2013 and 2015). Two studies used SF-36, and two
studies used SF-12 to describe participants’ health states.
Three of the 17 studies which used a generic PBM also used
theMLWHF condition-specific questionnaire to collect longer
term (median 29.4 month) follow-up data to describe HRQoL
for the purpose of deriving QALYs in a cost–utility analysis
that extended outcomes beyond the end of the initial trial.
These three cost-utility analyses (CUAs) were all undertaken
alongside the CARE-HF trial [11–13]. Of the remaining three
studies, two studies used patients own perceived health states
to derive QALYs [15, 25], one of which also described health
status using the EQ-5D visual analogue scale (VAS) [25]. The
final study [19] used the physician-reported NYHA assess-
ment to describe health status [32].
Valuation of HRQoL
Of the 17 studies using a generic PBM to describe health
status of the patients in their trials, most (n = 13) reported that
they applied an existing utility tariff for valuation. For the 13
studies using EQ-5D, eight studies applied the UK tariff in
which the EQ-5D-3L health states were valued by a sample of
the public using TTO methods, one study applied Australian
TTO weights, and one study applied the European EQ-net
weights, in which health states were valued using VAS
methods. The remaining three studies using EQ-5D to de-
scribe health status did not clearly report the method for de-
riving utilities [18, 24, 31]; although, in two studies, the
German and Spanish tariffs based on TTO methods would
appear to have been used to assign utility weights to the EQ-
5D health states [24, 31]. Both studies using the SF-36 and
one of the studies using the SF-12 to describe participants’
health status applied the SF-6D algorithm to assign utilities.
The SF-6D algorithm was developed based on the preferences
of a UK public sample for being in different health states,
using the SG valuation method [34]. The final study using
the SF-12 to measure participant health status [21] mapped
SF-12 results onto the Health Utilities Index Mark 3 (HUI-3)
and the EQ-5D-3L in two separate base case analyses using a
conversion formula based on the results from a low-income
minority population [35].
The three studies which used the MLWHF questionnaire, a
condition-specific HRQoL instrument for which there is no
utility tariff available, to both describe and value HRQoL
alongside the EQ-5D-3L, were CUAs undertaken alongside
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Table 3 Methods to derive QALYs applied in the studies (20 cost–utility analyses)
Author and year Measure of HRQoL
collected in trial
Valuation method used
to assign utility weights
Follow-up Mean difference between
groups at follow-up (QALYs
per person) (95% CI) significance
Agvall et al. (2014)
[19]
NYHA class Published study in which patients
valued own health using TTO,
categorised by NYHA class [32]
Baseline and 12 months − 0.01 NS
Blomstrom et al. (2008)
[11]
EQ-5D-3L† UK weights (TTO) [33] Within trial: Baseline, 3 months Within trial 0.20
Extrapolated 0.91
NR
MLWHF MLWHF mapped to EQ-5D-3L [12] Extrapolated beyond trial: 18
months and end of study
(mean follow-up 29.4 months)
Boyne et al. (2013)
[20]
EQ-5D-3L UK weights (TTO) [33] Baseline, 3, 6 and 12 months − 0.0031 (− 0.0552 to 0.0578) NS
Calvert et al. (2005)
[12]
EQ-5D-3L† UK weights (TTO) [33] Within trial: Baseline, 3 months Extrapolated 0.22 (0.13 to 0.32)#
MLWHF MLWHF mapped to EQ-5D-3L Extrapolated: 18 months and end
of study (mean follow-up 29.4 months)
Capomolla et al. (2002)
[15]
Own health state Patients in trial used TTO
to value own health state
12 months 0.080
p < 0.01
Cui et al. (2013)
[27]
SF-36 Converted into SF-6D UK
weights (SG)‡ [34]
Baseline, 3 (6 and 12) months* I2 0.04
NR
Hansson et al. (2016)
[16]
EQ-5D-3L UK weights (TTO) [33] Baseline and 3 months 0.001
NR
Hebert et al. (2008)
[21]
SF-12 Mapped to HUI-3 [35] Baseline, 3, 6, 9 and 12 months 0.0497 (0.0054 to 0.0940)#
Mapped to EQ-5D-3L [35] 0.0430 (0.0012 to 0.0848)#
Maniadakis et al. (2011)
[13]
EQ-5D-3L† UK weights (TTO) [33] Within trial: 3 months Extrapolated 1.41
Within trial 0.20
NR
MLWHF MLWHF mapped to EQ-5D-3L [12] Extrapolated: 18 months and end of study
Maru et al. (2015)
[22]
EQ-5D-3L Australian weights (TTO) [36] Baseline and 6, 12, 18 months,
extrapolated to extended
follow-up (median 3.2 years)
0.26 (− 0.03 to 0.56)
p = 0.078
Mejia et al. (2014)
[23]
EQ-5D-3L UK weights (TTO) [33] Baseline, 3, 6 and 12 months − 0.02 (− 0.09 to 0.05)
p = 0.537
Neumann et al. (2015)
[24]
EQ-5D (3 or 5-level NR) German weights (source NR) Baseline and 6 months 0.022
p = 0.02
Patel et al. (2008)
[25]
EQ-5D-3L (VAS)
Own health state
No tariff, i.e. VAS for own health state
SG to value own health state
Baseline and 12 months 0.07 NS
0.01 NS
Postmus et al. (2016)
[17]
SF-36 Converted into SF-6D UK
weights (SG)‡ [34]
Baseline, 1, 6, 12 and 18 months I1 0.023
I2 0.004
NR
Reed et al. (2010)
[29]
EQ-5D-3L US weights (TTO) Baseline, quarterly through first year
and annually at final visit (max. 4 years)
0.03 (− 0.06 to 0.11)
NS
Reilly et al. (2015)
[26]
EQ-5D-3L US weights (TTO) [37] Baseline and 6 months 0.04 (− 0.04 to 0.11)
NS
H
eart
Fail
R
ev
Table 3 (continued)
Author and year Measure of HRQoL
collected in trial
Valuation method used
to assign utility weights
Follow-up Mean difference between
groups at follow-up (QALYs
per person) (95% CI) significance
Sahlen et al. (2016)
[18]
EQ-5D-3L Tariff NR Baseline and 6 months (± 2 weeks) 0.03
p = 0.026
Sánchez et al. (2010)
[31]
EQ-5D-3L Methods unclear, appears to be TTO (Spain) Baseline and 6 months 0.227 (utility§)
p < 0.01
Sanders-van Wijk et al. (2013)
[30]
SF-12 Converted into SF-6D [34] Baseline, 12 and 18 months 0.05 (− 0.02 to 0.11)
p = 0.35
Zanaboni et al. (2013)
[28]
EQ-5D (3L assumed) European EQ-net (VAS) [38] Baseline and 16 months 0.065
p = 0.03
Italicised entries indicate signifiance level
NR not reported, I intervention, C control, NS not significant, I1 intervention 1, I2 intervention 2, I3 intervention 3,MLWHFMinnesota Living With Heart Failure questionnaire, TTO time trade-off, SG
standard gamble, VAS visual analogue scale, EQ-5D EuroQol, SF-36/SF-12 Short-Form Survey 36/12, NYHA New York Heart Association functional classification
*QALYs reported on results from first survey (3 months)
†Utilities at 18 months and end of study were estimated fromMLWHF scores collected at 18 months and end of study on the basis of a mixed model of the relationship between change in EQ-5D-3L score
to change in MLWHF
‡Assumption of UK Weights (SG) use
§QALYs calculated but utility weights reported only
#Confidence interval suggest significant but p-value not reported
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the CARE-HF trial [11–13]. They used the MLHF data col-
lected at a median of 29.4 months follow-up to model utility
outcomes beyond the initial period of the trial. The authors
assigned utility weights to model utility outcomes beyond the
initial period of the trial based on a mixed model mapping the
relationship between change in EQ-5D-3L and change in
MLWHF which were both completed at baseline and 90 days
follow-up in the trial [12].
Of the remaining three studies, two studies used patients’
direct valuation of their own health states to assign utility
weights (one using the TTO approach [15] and one using
the EQ-5D VAS and SG approaches [25]). The final study in
which participants health status was described using NYHA
[19] assigned utility weights to NYHA classes using a pub-
lished study in which elderly patients with heart failure valued
their own health status using TTO methods [32].
Change in QALY reported by the studies
We attempted to examine whether the evaluations undertaken
alongside trials identified significant changes in QALYs
(Table 3). Only seven of the 20 analyses undertaken alongside
trials reported significant incremental QALY gains, ranging
between 0.022 and 0.22 QALYs per person over follow-up
periods of up to a mean of 29.4 months. Interestingly, none of
these generated utility weights using the combination of EQ-
5D-3L with the UK TTO tariff, despite this being the most
common approach to generate utility weights across the stud-
ies. Instead, the seven studies [12, 15, 18, 21, 24, 28, 31]
reporting significant QALY differences used the EQ-5D-3L
with US, Spanish or European utility weights, the EQ-5D (3L/
5L not stated) with German weights, the MLWHF mapped to
EQ-5D-3L, SF-12 mapped to EQ-5D/HUI-3 or direct TTO
valuation by patients to derive QALYs. Eight analyses [19,
20, 22, 23, 25, 26, 29, 30] did not report significant QALY
differences between interventions. Two of these used the EQ-
5D-3L to describe health states combined with the UK tariffs,
others used US (n = 2) or Australian (n = 1) tariffs to value the
gain, one used the SF-12 converted to SF-6D utility weights,
one used the EQ-5D-3L VAS scale to derive patient’s direct
valuations for health states and another used NYHA class with
utility weights derived from TTO from previous literature.
Cost–utility analyses of five trials [11, 13, 16, 17, 27] did
not report the significance of any change in QALY.
Cost-effectiveness of interventions
Table 4 summarises the overall findings of the 20 studies with
respect to the cost-effectiveness of interventions evaluated for
the management or treatment of heart failure. Overall, most
interventions were reported as being cost-effective using the
thresholds the studies applied to their own evaluations (which
were dependent upon country of study and relevant
international agency). The incremental cost-effectiveness ra-
tios (ICERs) ranged from a cost-saving of − 61,081 € [31] to
98,000 € [16] per QALY gained. Probabilities of being cost-
effective ranged from 0.08 at a 20,000 € threshold [39] to
around 1.0 at a 25,000 € threshold [13]. Eight interventions
were reported as being dominant [17, 18, 22, 26, 28–31] com-
pared to the control group, and one was reported as being
dominated [23]. Two studies did not publish cost per QALY,
and seven studies did not publish a cost-effectiveness proba-
bility estimate [15, 16, 18, 19, 25, 28, 31].
Quality of reporting (CHEERS checklist)
Table 4 shows scores for the CHEERS checklist, reported as a
percentage (%) out of a maximum score of 48. The quality of
reporting of the studies ranged from 62.5% [25] (probably due
to the small scale of this pilot study) to 97.9% [23].
Discussion
Although HF is associated with a large health care burden, this
systematic review identified rather few valid health economic
analyses of relevant RCTs suggesting that many economic
evaluations of HF interventions do not consider HRQoL as
an outcome measure. For example, a search of the NHSEED
(National Health Service Economic Evaluation) database
which holds comprehensive records of published health eco-
nomic evaluations identified 178 records with the term Bheart
failure^ or Bcardiac failure^ in the title (database available at
https://www.crd.york.ac.uk/CRDWeb/ search performed 4
January 2018). Moreover, Goehler et al. (2011) reviewed 34
decision-analytic modelled studies in HF, in which only 19
reported QALYs as an outcome measure. Nevertheless, most
(though not all) of the cost–utility analyses identified in this
review followed what is currently regarded as Bbest practice^
for the derivation of QALYs and their consideration in eco-
nomic evaluation [40, 41]. That is, they adopted generic mea-
sures, notably the EQ-5D-3L and SF-36 and its derivative
(SF-12) on which participating patients describe their own
health states, and then the preferences of a general population
sample were used to value improvements in HRQoL by
assigning utility weights from existing tariffs. The high fre-
quency with which the EQ-5D-3L was used is consistent with
the dominance of EQ-5D-3L in other clinical areas and the
prescriptive guidance fromNICE requiring EQ-5D-3L to gen-
erate utility weights in health technology assessments [2].
The methods used to derive QALYs in the identified stud-
ies were variable, however. In particular, they raise questions
in the context of heart failure, around several methodological
issues that are debated in the health state valuation literature.
To undertake cost–utility analyses utilising the QALY as an
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Table 4 Cost-effectiveness results of interventions (n = 20)
Author and year Intervention vs. control Results
Cost per QALY Cost-effective probability Quality (CHEERS) (%)
Agvall et al. (2014)
[19]
Management program vs. usual care NR NR 72.9
Blomstrom et al. (2008)
[11]
Pharmacological therapy (PT) with
cardiac resynchronisation therapy vs. PT alone
Denmark 4759 € (1553 € to 12,637 €),
Finland 3571 € (1169 € to 10,153 €),
Sweden 6493 € (2669 € to 17,482 €)
99% at 50,000 € threshold 77.1
Boyne et al. (2013)
[20]
Telemonitoring vs. usual care 40,321 € 48% at 50,000 € threshold 81.3
Calvert et al. (2005)
[12]
Pharmacological therapy (PT) with
cardiac resynchronisation therapy vs. PT alone
19,319 € (5482 € to 45,402 €) 83% at 29,400 € threshold 93.8
Capomolla et al. (2002)
[15]
Day-hospital management vs. usual care US$19,462 ($13,904 to $34,048) NR 75.0
Cui et al. (2013)
[27]
Health lines (I1) and Health lines and
in-house monitoring (I2) vs. standard treatment
CAD$2975* 85.8% at $50,000 threshold 85.4
Hansson et al. (2016)
[16]
Person-centred vs. conventional care 98,000 € NR 91.7
Hebert et al. (2008)
[21]
Nurse-managed disease management vs. usual care US$17,543 (−$139,295 to $458,900)
for EQ-5D conversion and US$15,169
(−$114,748 to $282,657) for HUI-3
64% at $50,000 threshold 93.8
Maniadakis et al. (2011)
[13]
Pharmacological therapy (PT) with cardiac
resynchronisation therapy vs. PT alone
6045 € (4292 € to 9411 €) ~100% at 25,000 € threshold 91.7
Maru et al. (2015)
[22]
Home vs. clinic based care Cost saving of AU$13,100 with
an increase of 0.26 QALYs
96% at $20,000 91.7
Mejia et al. (2014)
[23]
Nurse facilitated cognitive behavioural
self-management programme vs. usual care
£69.49 per reduction of 0.004
(− 0.06 to 0.05) QALYs
45% at £20–30,000 threshold 97.9
Neumann et al. (2015)
[24]
Nurse-led management programme vs. usual care 49,335 € Between 55 and 90% up to 105,000 € 79.2
Patel et al. (2008)
[25]
Home vs. conventional care NR NR 62.5
Postmus et al. (2016)
[17]
Basic (I1) and intensive (I2) additional
nurse support vs. usual care
Cost saving of 77 € for (I1) with QALY
gain of 0.023 against usual care
and cost saving 1178 € and I2
and 0.004 QALYs against (I2)
62% and 8% at 20,000 € threshold 72.9
Reed et al. (2010)
[29]
Exercise training plus usual care vs. usual care Cost saving of US$4300 with
an increase of 0.03 QALYs
74.4% at $100,000 threshold 85.4
Reilly et al. (2015)
[26]
Self-care vs. usual care Cost saving of US$7647‡ 79.3%† 75.0
Sahlen et al. (2016)
[18]
Palliative advanced home and heart failure
care vs. usual care
Cost saving of 1649 €
and additional 0.25 QALYs
NR 87.5
Sánchez et al. (2010)
[31]
Peritoneal dialysis vs. conservative therapy − 61,081 € NR 64.6
Sanders-van Wijk et al. (2013) 93% at $50,000 threshold 93.8
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outcome, it is necessary to both accurately measure change in
HRQoL and to appropriately assign the utility value associat-
ed with that change using public preferences. Only generic
PBMs which are designed to be used across a range of differ-
ent conditions (such as the EQ-5D) are available as validated
instruments to both measure and value HRQoL in HF. These
have the advantage that if they are used consistently, they
provide a common approach to measurement and valuation
of HRQoL across all conditions, thus allowing a direct com-
parison of the benefit of allocating resources to heart failure
alongside the benefit of allocating resources to address other
health conditions. Condition-specific measures of HRQoL are
more sensitive to change in HRQoL in HF, but existing instru-
ments are not preference-based and so do not have a utility
valuation tariff to derive QALYs [4, 6, 7, 42]. This might
explain why only three cost–utility analyses (based on a single
trial) attempted to use condition-specific HRQoL data to de-
rive QALYs. The need for sensitive condition-specific mea-
sures to be used alongside generic measures to ensure the
accurate capture and valuation of change in HRQoL has been
raised previously across a range of clinical areas [5], including
HF [43]. Indeed some international reimbursement agencies,
such asNICE, allow the inclusion of analyses using condition-
specific measures in sensitivity analyses to support the ap-
praisal of health care interventions [2]. However, none of the
studies identified in this review tested the impact on the cost-
effectiveness estimates of using weights based on a condition-
specific preference-based measure as opposed to a generic
preference-based measure in the evaluation. Therefore, we
are unable to provide further evidence to inform the debate
on the relative value of generic vs. condition-specific mea-
sures in the setting of heart failure.
This review found mixed results in QALYoutcomes; with
similar numbers of studies finding significant, non-significant
or unreported significance in differences between interven-
tions in QALYs. This may be because the intervention was
not effective, has a problem with trial size or design or the
failure of the HRQoL tool to accurately capture change. Some
measures used may not be responsive to changes in HRQoL.
This would not be surprising as some trials failed to show
improvements in HRQoL despite reductions in mortality and
hospital readmission [44]. Alternatively, it may be that any
change in HRQoL is captured, but the improvements in
HRQoL are not considered meaningful according to the pref-
erences of members of the public when they are valued and
converted to QALYs. Within the review, a pilot study [25]
used both the EQ-5DVAS and the SG to derive utility weights
for the intervention and control groups in the same sample,
giving a different mean difference in QALYs between groups
across the two methods, suggesting they do not measure or
value HRQoL in the same way as would be expected. This
threatens the convergent validity of the VAS and SG methods
to value change in HRQoL within the HF population. ThisT
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lack of concordance between VAS, TTO and SG has been
widely reported outside of HF [45]. Although most studies
in the review used valuation tariffs that were derived using
TTO methods, some used SG or VAS approaches to derive
utility weights. The variation in methods for deriving QALYs
identified in this review is therefore a concern and potentially
threatens the consistency of the evidence on any decisions
based on the findings of these evaluations. Nevertheless, the
interventions reported generally appeared to be cost-effective
when compared to specified decision-making thresholds for
willingness to pay for a QALY gain. Therefore, it is possible
that the variable statistical significance of the QALY gains
identified in this review and the possible suboptimal sensitiv-
ity of some approaches to measuring and valuing HRQoL
may not alter decision-making. However, reporting bias is
also possible; interventions that are cost-effective are more
likely to be published.
One possible solution to lack of sensitivity to change in
generic PBM has been to measure change in HRQoL using
a condition-specific measure and then to map these back to a
generic PBM in order to generate utility weights [9, 46].
However, this may not maintain the sensitivity of the
condition-specific measure if the generic PBM is not sensitive
to these symptoms. This mapping approach was only ob-
served within this review for the CARE-HF trial [11–13]. It
has also been undertaken in several model-based studies in HF
[39, 47, 48] but has received criticism regarding the potential
error component in the algorithm used to map utility weights
to the MLWHF [47]. Mapping is not a panacea and has been
considered theoretically inferior [40, 46]. For example, the
conversion of generic SF-12 scores into two different mea-
sures to derive QALYs in one study in this review [21] result-
ed in two different mean difference values between groups at
follow-up, likely because the EQ-5D-3L does not contain a
dimension for energy or vitality, leading to small and non-
significant coefficients when mapped and potentially errone-
ous mapping values [49]. One study [19] within the review
used a physician-reported measure, the NYHA to calculate
QALYs by using a utility weighting from previous literature
[32], which centres on domains of physical health and func-
tional status as opposed to HRQoL. There is inherent uncer-
tainty associated with both designating an NYHA class and
the algorithm used to estimate utility weights, and it may not
fully capture individuals’ HRQoL [50]. The three studies
mapping MLWHF to EQ-5D-3L for the CARE-HF trial
[11–13] identified in the review and several modelling studies
[39, 51] all used the same algorithm reported by Calvert et al.
[12]. It is unclear whether the method of estimation of weights
on the basis of a mixed model relationship between the change
in the EQ-5D-3L and MLWHF change is robust or not in
capturing and modelling HRQoL changes. Standard guide-
lines exist for best practice methods in mapping studies
[52–54], but the mapping algorithm utilised cannot be
assessed against these as it has not been fully published or
peer reviewed, only appearing in summary form in a cost
utility analysis publication [12].
All of the studies identified in this review used the trial
participants to describe their own health state for valuation,
mostly via completion of a HRQoL instrument or a visual
analogue scale (although, one study used physician assess-
ment of NYHA class rather than the patient’s own perception
of their health state as the basis for valuation). However, not
all studies assigned the preferences of a general public sample
to derive the valuation. Three studies used the preferences of
patients with heart failure as the basis for the utility weights
used to derive QALYs [15, 19, 25]. Arguments have been
advanced in the literature both for and against the use of pa-
tient as opposed to public preferences for the valuation of
health states [55–57]. However, consensus is generally
aligned with the use of public preferences where the purpose
of an evaluation is to inform resource allocation cross the
health system [40], and NICE requires the use of public rather
than patient preferences in their reference case [2].
Limitations
Whilst we were inclusive in our approach to selecting studies,
the diversity of the literature and necessity for narrow search
terms may mean that some potentially relevant papers were
missed. We reduced this risk by hand-searching identified
papers. Publication bias is likely, but this is beyond the control
of a systematic review. A language bias is also possible, as
only published in English were retrieved. Our review only
included trials which reported QALYs; thus, it does not pres-
ent a complete picture of howHRQoL is measured or reported
in heart failure. Trials that may havemeasured HRQoL but not
derived QALYs, measured other aspects of the Bpatient
journey^ (e.g. the COMET study [58]) or studies reporting
QALYs but principally using a modelling approach were ex-
cluded. This was a purposeful decision, since our focus was
on how HRQoL was valued and QALYs were derived in
primary research in heart failure.
Most participants included in this review were older
men in NYHA class II or III, which is consistent with
the major i ty of those enrol led in RCTs of HF.
Limitations at the study and outcome level include the
amount of missing HRQoL data, with some studies
reporting 22–23% [16], 37% [30] and 12% [28] of partic-
ipants with incomplete data. Approaches for dealing with
missing data included the use of last-observation-carried-
forward [11, 13, 22, 29] and imputation methods [20, 21,
23, 28], both of which have drawbacks in measuring
HRQoL in the long term. In clinical trials where mortality
is high and a utility weight of zero is assigned from the
time of death, this may make a large contribution to the
QALY value.
Heart Fail Rev
Conclusions
Comparatively, few economic evaluations undertaken alongside
clinical trials in patients with HF report QALY as an outcome
measure. This is unfortunate given the importance of HRQoL (in
addition to survival) as a treatment goal, both from a patient and
health care professional’s perspective and for the determination
of cost-effectiveness. This review suggests that the published
evidence on cost-effectiveness that might underpin decisions re-
garding resource allocation for HF interventions is based on a
variety of methodological approaches and usually relies on the
sensitivity of generic measures. A review nearly 20 years ago
suggested the optimal method of assessing HRQoL was a com-
bination of both generic and condition-specific measures [8].
Findings suggest there has been no substantial progress in the
most effective way tomeasure and valueHRQoL for the purpose
of deriving QALYoutcomes in people with HF.
Key points
& The accurate valuation of HRQoL is important to inform
resource allocation decisions.
& We found few economic evaluations undertaken alongside
clinical trials in heart failure have reported QALYs as an
outcome.
& Trial-based economic evaluations have generally used generic
measures ofHRQoL to deriveQALYs, but there is substantial
variation in approach.
& Less than half the studies identified reported significant
QALY gains between intervention groups
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